



## X4 Pharmaceuticals to Present Clinical Data at Upcoming Oncology Medical Conferences

October 9, 2018

*Data to highlight X4P-001-IO, orally bioavailable CXCR4 antagonist, in advanced renal cell carcinoma and melanoma*

**CAMBRIDGE, Mass., October 9, 2018** – [X4 Pharmaceuticals](#), a clinical-stage biotechnology company developing novel [CXCR4](#) allosteric antagonist drug candidates designed to improve immune cell trafficking to treat rare diseases and cancer, has been selected to present data on X4P-001-IO, a CXCR4 antagonist, at two upcoming oncology medical meetings. The company will present clinical data on X4P-001-IO in advanced renal cell carcinoma (RCC) in a Poster Discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress, taking place October 19-23 in Munich. X4 will also present clinical data on X4P-001-IO in melanoma at the 33<sup>rd</sup> Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 9-11 in Washington DC.

Details of the presentations on X4P-001-IO are as follows:

### **European Society for Medical Oncology (ESMO)**

**Title:** A Phase 1a/2b Trial of the CXCR4 Inhibitor X4P-001 and Nivolumab for Advanced Renal Cell Carcinoma (RCC) that is Unresponsive to Nivolumab Monotherapy

**Session Type:** Poster Discussion session – Immunotherapy of Cancer 1

**Date & Time:** Oct. 20, 2018, 4:45 – 5:45 p.m. CET

**Location:** ICM – Room 14b

**Presentation #:** 1134PD

**Poster Display:** Designated Poster Discussion area in Hall B4, displayed for the duration of the Congress

### **Society for Immunotherapy of Cancer (SITC)**

**Title:** X4P-001, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and tumor inflammatory status in the microenvironment of melanoma

**Session Type:** Poster session

**Date & Time:** Friday, Nov. 9, from 8 a.m. – 8 p.m. ET

Saturday, Nov. 10, from 8 a.m. – 8:30 p.m. ET

**Location:** Hall E

**Poster #:** P53

### **About X4P-001-IO in Cancer**

[X4P-001-IO](#) is an investigational selective, oral, small molecule antagonist of C-X-C receptor type 4 (CXCR4). CXCR4 is a chemokine receptor present in abundance on certain immune cells and cancer cells and it plays a critical role in immune cell trafficking, infiltration and activation in the tumor microenvironment. CXCR4 signaling is disrupted in a broad range of cancers, facilitating tumor growth by allowing cancer cells to evade immune detection and creating a pro-tumor microenvironment. X4P-001-IO has the ability to help restore immunity within the tumor microenvironment and has the potential to enhance the anti-tumor activity of approved and emerging oncology agents, such as checkpoint inhibitors and targeted therapies. X4P-001-IO is being investigated in several clinical studies in solid tumors.

### **About X4 Pharmaceuticals**

[X4 Pharmaceuticals](#) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer. The Company's oral small molecule drug candidates antagonize the [CXCR4](#) pathway, which plays a central role in immune surveillance. X4's most advanced product candidate is in a Phase 2/3 clinical trial in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease and is currently under investigation in multiple clinical trials in solid tumors. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA. For more information, visit [x4.thevatesnetwork.com](#).

### **Contact:**

Kathryn Morris  
914-204-6412

